Caprock Group LLC Invests $2.99 Million in Bristol Myers Squibb Company $BMY

Caprock Group LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 63,313 shares of the biopharmaceutical company’s stock, valued at approximately $2,987,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Gateway Investment Advisers LLC lifted its holdings in shares of Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares during the period. CWA Asset Management Group LLC lifted its stake in Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after acquiring an additional 30,909 shares during the period. Commonwealth Retirement Investments LLC boosted its holdings in shares of Bristol Myers Squibb by 24.6% in the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 11,690 shares during the last quarter. Stephens Inc. AR increased its stake in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares during the period. Finally, Railway Pension Investments Ltd raised its holdings in shares of Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after purchasing an additional 40,300 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $59.78 on Friday. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The stock has a market capitalization of $121.69 billion, a PE ratio of 17.33, a P/E/G ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a fifty day moving average of $55.16 and a two-hundred day moving average of $49.35.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Guggenheim reaffirmed a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Finally, UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the company from $46.00 to $65.00 in a report on Wednesday, January 7th. Eight investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.